SuperworthCronos EPS CRON
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- $0.20
- Latest quarter, Q2 FY26
- $0.09
- Fiscal year 2025
- −$0.01
- −110% on the year before
Cronos' earnings per share was $0.20 over the twelve months to Jun 30, 2026, up 300% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.09.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.01 | −110% |
| FY2024 | $0.10 | n/a |
| FY2023 | −$0.19 | n/a |
| FY2022 | −$0.45 | n/a |
| FY2021 | −$1.07 | n/a |
| FY2020 | −$0.24 | −111% |
| FY2019 | $2.28 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.09 | n/a | $0.20 | |
| Q1 FY26 | $0.04 | +100% | $0.01 | |
| Q4 FY25 | $0.00 | −100% | −$0.01 | |
| Q3 FY25 | $0.07 | +250% | $0.10 | |
| Q2 FY25 | −$0.10 | n/a | $0.05 | |
| Q1 FY25 | $0.02 | n/a | $0.13 | |
| Q4 FY24 | $0.11 | n/a | $0.10 | |
| Q3 FY24 | $0.02 | n/a | −$0.13 | |
| Q2 FY24 | −$0.02 | n/a | −$0.15 | |
| Q1 FY24 | −$0.01 | n/a | −$0.15 | |
| Q4 FY23 | −$0.12 | n/a | −$0.19 | |
| Q3 FY23 | $0.00 | n/a | −$0.28 |
Against its peers
Companies in Chemicals nearest Cronos' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CRONCronos | $0.20 | +300% a year |
| FTKFlotek Industries | $0.99 | +125% a year |
| ROGRogers | $1.75 | |
| NGVTIngevity | $1.47 | |
| IOSPInnospec | $4.90 | +545% a year |
| FULFuller H B | $3.59 | +72% a year |
| WDFCWD 40 | $6.58 | +4% a year |
| AVNTAvient | $1.85 | +43% a year |
| CBTCabot | $3.54 | −54% a year |
| CSWCSW Industrials | $7.29 | −13% a year |
| BCPCBalchem | $5.09 | +16% a year |
| Peer median | $3.56 |
Where Cronos ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Cronos
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.